# Molecular diagnostic and prognostic signatures for PTCL

> **NIH NIH UH3** · UNIVERSITY OF NEBRASKA MEDICAL CENTER · 2021 · $246,546

## Abstract

Abstract
Peripheral T-cell lymphomas (PTCL) represent approximately 10-12% of all NHL in the western world
and generally exhibit poor prognosis with standard chemotherapy. Another significant challenge is that
using current diagnostic approaches, approximately 30-50% of PTCL cases cannot be assigned to a
specific entity and are categorized as PTCL-not otherwise specified (PTCL-NOS). Of the more common
PTCL entities recognized by WHO classification, we have defined robust molecular gene expression
signatures that can differentiate the five PTCLs entities: angioimmunoblastic T-cell lymphoma (AITL),
anaplastic lymphoma kinase positive anaplastic large-cell lymphoma (ALK(+)ALCL), ALK-negative
anaplastic large-cell lymphoma (ALK(-)ALCL), adult T-cell leukemia/lymphoma (ATLL), and extranodal
natural killer/T-cell lymphoma (ENKTCL). PTCL-NOS can now be separated into two distinct molecular
subgroups (the TBX21 and GATA3 subgroups). A prognostic model for AITL has also been developed.
Overall, these represent more than 80% of all the PTCL. The aim of this proposal is to consolidate these
diagnostic and prognostic signatures into a single technology platform that can be applied to formalin
fixed, paraffin embedded tissues (FFPET) to improve standardization and accuracy of PTCL diagnosis.
This platform will be applicable to not only routine clinical applications, but will help to stratify patients in
prospective clinical trials for new therapeutic agents. We will validate these signatures in a CLIA setting
at two different locations for reproducibility and will subsequently evaluate specimens from six clinical
trials. Clinical samples and data essential to develop these assays will be obtained from the two major
consortiums: the International PTCL Project (IP-PTCL) and the Lymphoma and Leukemia Molecular
Profiling Project (LLMPP), which had provided specimens and clinical data for the GEP study. Additional
institutions will participate to provide new cases for validation studies. We are uniquely positioned to
accomplish this work by having derived the “gold standard” diagnostic and prognostic signatures of these
lymphomas, as well as having matching fresh frozen tissue and FFPET blocks. Our group has used a
similar approach to develop the “Lymph2Cx” assay for a robust distinction between the GCB and ABC
subtype of diffuse large B-cell lymphoma.

## Key facts

- **NIH application ID:** 10226182
- **Project number:** 5UH3CA206127-05
- **Recipient organization:** UNIVERSITY OF NEBRASKA MEDICAL CENTER
- **Principal Investigator:** Wing C. Chan
- **Activity code:** UH3 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $246,546
- **Award type:** 5
- **Project period:** 2017-04-01 → 2023-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10226182

## Citation

> US National Institutes of Health, RePORTER application 10226182, Molecular diagnostic and prognostic signatures for PTCL (5UH3CA206127-05). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10226182. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*